pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·May 1·1 min read
save

Boehringer Ingelheim names Christie Bloomquist as SVP of US corporate affairs and head of its Cares Foundation

May 1, 2026·read at Endpoints ↗Neutral

Boehringer Ingelheim announced that Christie Bloomquist has been appointed senior vice president of corporate affairs for its U.S. human pharmaceutical business.

In addition to overseeing corporate affairs, Bloomquist will serve as president of the Boehringer Cares Foundation, the company’s charitable arm focused on health and community initiatives.

The announcement comes as BlueRock’s chief scientific officer is reported to be leaving the company, though details of that departure were not provided.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Boehringer appoints pharma veteran for corporate affairs post; BlueRock CSO heads for the exit”

read at Endpoints ↗
90 words · retrieved May 1
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
BOEHRINGER INGELHEIM2Boehringer Ingelheim Corp2

related stories

  • Aug 18LEO adds to dermatology portfolio with $435M deal for late-stage rare disease drugBioSpace
  • Aug 17Leo ‘really strengthening’ pipeline with $435M deal for Tanabe rare skin disease drug awaiting FDA nodFierce Biotech
  • Aug 17Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vagueFierce Biotech
  • Aug 13Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decisionFierce Biotech
  • Aug 11After billions in deals, Insilico CEO promises: ‘You haven't seen anything yet’BioSpace